8-K: Phio Pharmaceuticals Appoints Dr. R. Todd Plott to Board
Director Appointment
Phio Pharmaceuticals Corp. announced the appointment of Dr. R. Todd Plott, a dermatologist with extensive research and FDA experience, to its Board of Directors.
Summary
- Phio Pharmaceuticals Corp. has appointed R. Todd Plott, M.D., to its Board of Directors, increasing the board size to six members.
- Dr. Plott is a board-certified dermatologist with over 30 years of experience in dermatologic care, research, and innovation.
- He is also a former member of the FDA Dermatologic and Ophthalmic Drug Advisory Committee (2016-2021).
- Dr. Plott will serve until the 2026 annual meeting of stockholders and has been appointed to the Board's Governance Committee.
- He will receive standard compensation and equity awards for non-employee directors.
- The appointment was announced via a press release on July 21, 2026.
Sentiment
Score: 6
Explanation: StockSavvy.ai views this as a neutral to slightly positive development, as it strengthens the board's expertise without immediate financial implications.
Positives
- Appointment of Dr. R. Todd Plott brings significant expertise in patient care, dermatologic research, and commercialization to the Board.
- Dr. Plott's experience as a former FDA advisory committee member is valuable for regulatory interactions.
- His background in clinical trials and drug development will support the advancement of Phio's pipeline, particularly PH-762.
Risks
- The company's actual results may differ materially from forward-looking statements due to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and outside of its control.
- Risks include the impact of future FDA interactions, inflationary pressures, recession fears, and the development of product candidates.
- Other risks involve the ability to execute business strategies, advance candidates into clinical development, obtain regulatory filings and approvals, and commercialize products.
- Manufacturing and supply capabilities for clinical and commercial use are also potential risks.
- Intellectual property protection and the ability to obtain future financing are also identified risks.
Future Outlook
The company expects FDA submissions to clarify next steps for the PH-762 development program and is planning a non-clinical toxicology study. They believe they have sufficient capital for ongoing clinical development, operational requirements, and strategic initiatives.
Management Comments
- Dr. Plotts exceptional experience through his dermatology practice as well as clinical development expertise provides a valuable resource to Phio as we advance PH-762 for squamous cell carcinoma.
- Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL gene silencing technology to eliminate cancer.
Industry Context
StockSavvy.ai notes that the appointment of experienced medical professionals to biopharmaceutical boards is a common strategy to enhance clinical and regulatory expertise, particularly for companies advancing novel therapies like Phio's siRNA platform for cancer treatment.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Board Member | N/A | R. Todd Plott, M.D. | 2026-07-20 | Board expansion and appointment to enhance expertise. |
| Member of Governance Committee | N/A | R. Todd Plott, M.D. | 2026-07-20 | Appointment to committee. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Board Size Increase | The size of the Board of Directors was increased to six members. | 2026-07-20 | Allows for addition of specialized expertise. |
| Indemnification Agreement | Dr. R. Todd Plott, M.D. will enter into the Company's standard form of indemnification agreement. | 2026-07-20 | Standard practice to protect directors from liabilities arising from their service. |
Stakeholder Impact
- Shareholders may view the addition of experienced board members positively, potentially enhancing strategic direction and oversight.
- Employees may benefit from strengthened leadership and a clearer path for product development.
- Creditors and suppliers may see increased stability with enhanced board expertise.
Next Steps
- Dr. R. Todd Plott will serve on the Board until the 2026 annual meeting of stockholders.
- Dr. Plott will serve as a member of the Board's Governance Committee.
- The company intends to submit to the FDA to propose and seek guidance for next steps in clinical study design for PH-762.
- The company is planning a non-clinical toxicology study for PH-762.
Key Dates
| Date | Description |
|---|---|
| 2016-01-01T00:00:00.000Z | Start of Dr. R. Todd Plott's service on the FDA Dermatologic and Ophthalmic Drug Advisory Committee. |
| 2021-12-31T00:00:00.000Z | End of Dr. R. Todd Plott's service on the FDA Dermatologic and Ophthalmic Drug Advisory Committee. |
| 2026-03-05T00:00:00.000Z | Date of filing of the Company's Annual Report on Form 10-K. |
| 2026-07-20T00:00:00.000Z | Effective date of Dr. R. Todd Plott's appointment to the Board of Directors. |
| 2026-07-21T00:00:00.000Z | Date of the press release announcing Dr. R. Todd Plott's appointment. |
| 2026-07-21T00:00:00.000Z | Date of the Form 8-K filing. |
| 2026-01-01T00:00:00.000Z | Expected date of the 2026 annual meeting of stockholders (Dr. Plott to serve until this meeting). |
Keywords
Phio Pharmaceuticals, Board of Directors, R. Todd Plott, Dermatology, siRNA, Oncology, PH-762, Clinical Trials
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.